BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 21289637)

  • 1. AAV6-mediated gene silencing fALS short.
    Mandel RJ; Lowenstein PR; Byrne BJ
    Mol Ther; 2011 Feb; 19(2):231-3. PubMed ID: 21289637
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuroprotection by gene therapy targeting mutant SOD1 in individual pools of motor neurons does not translate into therapeutic benefit in fALS mice.
    Towne C; Setola V; Schneider BL; Aebischer P
    Mol Ther; 2011 Feb; 19(2):274-83. PubMed ID: 21102563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA interference protects against ALS in mouse model.
    Burton A
    Lancet Neurol; 2005 May; 4(5):274-5. PubMed ID: 15861555
    [No Abstract]   [Full Text] [Related]  

  • 4. RNAi therapy: dominant disease gene gets silenced.
    Xu Z; Xia XG
    Gene Ther; 2005 Aug; 12(15):1159-60. PubMed ID: 15858609
    [No Abstract]   [Full Text] [Related]  

  • 5. Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis.
    Miller TM; Kaspar BK; Kops GJ; Yamanaka K; Christian LJ; Gage FH; Cleveland DW
    Ann Neurol; 2005 May; 57(5):773-6. PubMed ID: 15852369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic AAV6 delivery mediating RNA interference against SOD1: neuromuscular transduction does not alter disease progression in fALS mice.
    Towne C; Raoul C; Schneider BL; Aebischer P
    Mol Ther; 2008 Jun; 16(6):1018-25. PubMed ID: 18414477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lentiviral and adeno-associated vector-based therapy for motor neuron disease through RNAi.
    Towne C; Aebischer P
    Methods Mol Biol; 2009; 555():87-108. PubMed ID: 19495690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis.
    Wang LJ; Lu YY; Muramatsu S; Ikeguchi K; Fujimoto K; Okada T; Mizukami H; Matsushita T; Hanazono Y; Kume A; Nagatsu T; Ozawa K; Nakano I
    J Neurosci; 2002 Aug; 22(16):6920-8. PubMed ID: 12177190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Gene therapy of ALS with RNA interference].
    Yokota T
    Rinsho Shinkeigaku; 2009 Nov; 49(11):821-3. PubMed ID: 20030220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyotrophic lateral sclerosis and gene therapy.
    Miller TM; Smith RA; Cleveland DW
    Nat Clin Pract Neurol; 2006 Sep; 2(9):462-3. PubMed ID: 16932606
    [No Abstract]   [Full Text] [Related]  

  • 11. [Gene therapy of ALS with short interfering RNA].
    Yokota T
    Brain Nerve; 2007 Oct; 59(10):1187-94. PubMed ID: 17969360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis.
    Ding H; Schwarz DS; Keene A; Affar el B; Fenton L; Xia X; Shi Y; Zamore PD; Xu Z
    Aging Cell; 2003 Aug; 2(4):209-17. PubMed ID: 12934714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo.
    Xia X; Zhou H; Huang Y; Xu Z
    Neurobiol Dis; 2006 Sep; 23(3):578-86. PubMed ID: 16857362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral delivery of antioxidant genes as a therapeutic strategy in experimental models of amyotrophic lateral sclerosis.
    Nanou A; Higginbottom A; Valori CF; Wyles M; Ning K; Shaw P; Azzouz M
    Mol Ther; 2013 Aug; 21(8):1486-96. PubMed ID: 23732987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nerve injection of viral vectors efficiently transfers transgenes into motor neurons and delivers RNAi therapy against ALS.
    Wu R; Wang H; Xia X; Zhou H; Liu C; Castro M; Xu Z
    Antioxid Redox Signal; 2009 Jul; 11(7):1523-34. PubMed ID: 19344276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Research advances in gene therapy approaches for the treatment of amyotrophic lateral sclerosis.
    Nizzardo M; Simone C; Falcone M; Riboldi G; Rizzo F; Magri F; Bresolin N; Comi GP; Corti S
    Cell Mol Life Sci; 2012 May; 69(10):1641-50. PubMed ID: 22094924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Has gene therapy for ALS arrived?
    Miller TM; Cleveland DW
    Nat Med; 2003 Oct; 9(10):1256-7. PubMed ID: 14520369
    [No Abstract]   [Full Text] [Related]  

  • 18. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model.
    Azzouz M; Ralph GS; Storkebaum E; Walmsley LE; Mitrophanous KA; Kingsman SM; Carmeliet P; Mazarakis ND
    Nature; 2004 May; 429(6990):413-7. PubMed ID: 15164063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current developments in gene therapy for amyotrophic lateral sclerosis.
    Scarrott JM; Herranz-Martín S; Alrafiah AR; Shaw PJ; Azzouz M
    Expert Opin Biol Ther; 2015 Jul; 15(7):935-47. PubMed ID: 25959569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Finding a Treatment for ALS - Will Gene Editing Cut It?
    Al-Chalabi A; Brown RH
    N Engl J Med; 2018 Apr; 378(15):1454-1456. PubMed ID: 29641956
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.